In 2003, preclinical data about the combination of trastuzumab and pertuzumab in HER2 expressing breast cancer cells showed increased apoptosis and cell growth arrest when compared to trastuzumab alone [123]. The gene discussed is ERBB2; the disease is breast carcinoma.